Skip to content

Sumitovant Biopharma Logo

  • Home
  • Technology
  • Pipeline
  • Our Companies
  • Leadership
    • Leadership Voices
  • News & Events
  • Join Us
  • Contact
  • All
  • Altavant
  • Enzyvant
  • Myovant
  • Spirovant
  • Sumitovant
  • Urovant
  • January 26, 2022Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates
  • December 20, 2021Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg
  • December 10, 2021Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021
  • November 04, 2021Spirovant Presents Preclinical Data Showing SP-101 Restores CF Transmembrane Conductance Regulator Function at the 2021 North American Cystic Fibrosis Conference
  • October 12, 2021Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
  • October 08, 2021Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
  • September 16, 2021Sumitovant Biopharma Highlights Strong First Fiscal Quarter of 2021 with Significant Commercial and Clinical Achievements Across its Portfolio of Companies
  • September 13, 2021Altavant Sciences Highlights Ongoing Phase 2b ELEVATE 2 Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at European Respiratory Society Annual Congress
  • September 13, 2021Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate
  • September 09, 2021Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
  • « Previous 1 2 3 4 … 21 Next »
  • Careers
  • Terms of Use
  • Privacy Policy

Sumitovant Biopharma, Inc.

151 W. 42nd Street, 15th Floor

New York, NY 10036

info@sumitovant.com

© 2022 Sumitovant Biopharma

Sumitovant is a trademark of Sumitomo Pharma Co., Ltd.